Gadopentetate dimeglumine
Updates to Article Attributes
Gadopentetate dimeglumine (also known as MagnevistTM) is an extracellular intravenous contrast agent used in magnetic resonance imaging.
- linear, ionic molecule
- 100% renally excreted
- T1 relaxivity @ 1.5 T: 3.9-4.3
- concentration: 0.5 mmol/mL
- recommended dosage: 0.1 mmol/kg
Indications
As an extracellular contrast agent, gadopentetate dimeglumine can be useful in a wide range of MRI applications, including (but not limited to): hepatic imaging, pelvic imaging, cardiac imaging, brain and spine imaging, and musculoskeletal imaging.
Contraindications
There is an association between the use of gadolinium-based contrast agents (GBCAs) in patients with kidney dysfunction and nephrogenic systemic fibrosis (NSF), a rare, but serious, condition. As a result, the use of three GBCAs; gadopentetate dimeglumine (Magnevist®), gadodiamide (Omniscan®), and gadoversetamide (OptiMARK®) are contraindicated in patients with AKI or with chronic, severe kidney disease 2.
-</ul><h5>Indications</h5><p>As an extracellular contrast agent, gadopentetate dimeglumine can be useful in a wide range of MRI applications, including (but not limited to): hepatic imaging, pelvic imaging, cardiac imaging, brain and spine imaging, and musculoskeletal imaging.</p>- +</ul><h5>Indications</h5><p>As an extracellular contrast agent, gadopentetate dimeglumine can be useful in a wide range of MRI applications, including (but not limited to): hepatic imaging, pelvic imaging, cardiac imaging, brain and spine imaging, and musculoskeletal imaging.</p><h5>Contraindications</h5><p>There is an association between the use of <a href="/articles/gadolinium-contrast-agents">gadolinium-based contrast agents (GBCAs)</a> in patients with kidney dysfunction and <a href="/articles/nephrogenic-systemic-fibrosis">nephrogenic systemic fibrosis (NSF)</a>, a rare, but serious, condition. As a result, the use of three GBCAs; gadopentetate dimeglumine (Magnevist®), gadodiamide (Omniscan®), and gadoversetamide (OptiMARK®) are contraindicated in patients with AKI or with <a title="Chronic kidney disease" href="/articles/chronic-kidney-disease">chronic, severe kidney disease </a><sup>2</sup>.</p>
References changed:
- 2. FDA. Information for healthcare professionals: Gadolinium-based contrast agents for magnetic resonance imaging (marketed as Magnevist, MultiHance, Omniscan, OptiMARK, ProHance). link: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-warnings-using-gadolinium-based-contrast-agents-patients-kidney
Tags changed:
- nephrogenic systemic fibrosis
- gadolinium-based contrast media (gbcm)
- gadolinium-based contrast agents (gbcas)
- gadolinium contrast agents
Unable to process the form. Check for errors and try again.